BackHCW Biologics Overview

HCW Biologics Long Term Debt

Track HCW Biologics's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00
100.00% YoYΔ $-367151.00 vs prior year quarter

Peer trimmed avg / median

Loading

HCW Biologics Long Term Debt History

Loading

HCW Biologics vs. peers: Long Term Debt Comparison

Loading

HCW Biologics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

HCW Biologics (HCWB) FAQ

The latest long-term debt for HCWB is $0 as of June 2026. That compares with $370K in the prior-year period — down 100.0% year over year. Investors often review this figure alongside HCW Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HCWB's long-term debt moved from $370K to $0 — a 100.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in HCW Biologics's operating scale or balance-sheet position.

A long-term debt figure of $0 for HCWB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting HCWB's long-term debt ($0), review year-over-year change from $370K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack HCW Biologics's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.